Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis

Journal of Rheumatology

Volumn 36, Issue 10, 2009, Pages 2264-2268

  Schiopu, Elena ^a   Hsu, Vivien M ^b   Impens, Ann J ^a   Rothman, Jennifer A ^b   McCloskey, Deborah A ^b   Wilson, Julianne E ^b   Phillips, Kristine ^a   Seibold, James R ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

Author keywords

PDE 5 inhibitor; Raynaud phenomenon; Systemic sclerosis; Tadalafil

Indexed keywords

PLACEBO; TADALAFIL;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FLUID RETENTION; HEADACHE; HEART PALPITATION; HUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RAYNAUD PHENOMENON; SCORING SYSTEM; SIDE EFFECT; SLEEP DISORDER; SYSTEMIC SCLEROSIS; TREATMENT DURATION; VASOMOTOR DISORDER;

ADULT; CARBOLINES; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PILOT PROJECTS; PROSPECTIVE STUDIES; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME;

EID: 70450206401     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.090270     Document Type: Article

References (27)

1. Herrick A. Pathogenesis of Raynaud's phenomenon. Rheumatology 2005;44:587-596.
2. Thompson A, Shea B, Welch V, Fenlon D, Pope J. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum 2003;44:1841-1847.
3. Dziadzio M, Denton C, Smith R, Howell K, Blann A, Bowers E, et al. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 1999;42:2646-2655. (Pubitemid 30327186)
4. Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G, et al. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 2000;2(CD000953). (Pubitemid 30262041)
5. Kahaleh B. Vascular disease in scleroderma: mechanisms of vascular injury. Rheum Dis Clin North Am 2008;34:57-71. (Pubitemid 351329463)
6. Uckert S, Hedlund P, Andersson K, Truss M, Jonas U, Stief C. Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future. Eur Urol 2006;50:1194-1207. (Pubitemid 44692918)
7. Colglazier C, Sutej P, O'Rourke K. Severe refractory fingertip ulcerations in a patient with scleroderma: successful treatment with sildenafil. J Rheumatol 2005;32:2440-2442. (Pubitemid 41780663)
8. Gore J, Silver R. Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis. Ann Rheum Dis 2005;64:1387. (Pubitemid 41206274)
9. Caglayan E, Huntgeburth M, Karasch T, Weihrauch J, Hunzelmann N, Krieg T, et al. Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease. Arch Intern Med 2006;166:231-233. (Pubitemid 43144949)
10. Fries R, Shariat K, von Wilmowsky H, Bohm M. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation 2005;119:2980-2985. (Pubitemid 41612301)
11. Porst H. Phosphodiesterase type-5 inhibitors: a critical comparative analysis. EAU Update Series 2004;2:56-63.
12. Rosen R, Kotsis J. Overview of phosphodiesterase 5 inhibition in erectile dysfunction. Am J Cardiol 2003;92 Suppl:9M-18M. (Pubitemid 37386271)
13. Sung B, Hwang K, Jeon Y, Lee J, Heo Y, Kim J, et al. Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules. Nature 2003;425:98-102. (Pubitemid 37101725)
14. Boin F, Wigley F. Understanding, assessing and treating Raynaud's phenomenon. Curr Opin Rheumatol 2005;17(6):752-760. (Pubitemid 41546495)
15. Wright P. Comparison of phosphodiesterase type 5 (PDE5) inhibitors. Int J Clin Pract 2006;60:967-975. (Pubitemid 44082288)
16. Forgue S, Phillips D, Bedding A, Payne C, Jewell H, Patterson B, et al. Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokinetics. Brit J Clin Pharmacol 2007;63:24-35. (Pubitemid 44902874)
17. Impens AJ, Rothman J, Schiopu E, Cole JC, Dang J, Gendrano N, et al. Sexual activity and functioning in female scleroderma patients. Clin Exp Rheumatol 2009; Suppl 54: [in press].
18. Merkel PA, Herlyn K, Martin RW, Anderson JJ, Mayes MD, Bell P, et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum 2002;46:2410-2420.
19. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-590.
20. Wigley F, Korn J, Csuka M, Medsger TJ, Rothfield N, Ellman M, et al. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Arthritis Rheum 1998;41:670-677. (Pubitemid 28214985)
21. Gliddon A, Doré C, Black C, McHugh N, Moots R, Denton C, et al. Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. Arthritis Rheum 2007;56:3837-3846.
22. Baumhaekel M, Scheffler P, Boehm M. Use of tadalafil in a patient with a secondary Raynaud's phenomenon not responding to sildenafil. Microvascular Res 2005;69:178-179. (Pubitemid 40724579)
23. Maggiorini M, Brunner-La Roca H, Peth S, Fischler M, Bohm T, Bernheim A, et al. Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema: a randomized trial. Ann Intern Med 2006;145:497-506.
24. Affuso F, Palmieri E, Di Conza P, Guardasole V, Fazio S. Tadalafil improves quality of life and exercise tolerance in idiopathic pulmonary arterial hypertension. Int J Cardiol 2006;108:429-431. (Pubitemid 43339824)
25. Ghofrani H, Voswinckel R, Reichenberger F, Olschewski H, Haredza P, Karadas B, et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol 2004;44:1488-1496. (Pubitemid 39303954)
26. Shenoy P, Agarwal V, Kumar S, Choudhary SK, Jha LK, Singh U, Misra R. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double blind randomized cross over trial [abstract]. Arthritis Rheum 2008;58 Suppl:s402.
27. Friedman EA, Harris PA, Wood AJJ, Stein CM, Kurnik D. The effects of tadalafil on cold-induced vasoconstriction in patients with Raynaud's phenomenon. Clin Pharmacol Ther 2007;81:503-509 (Pubitemid 46452307)